Randomized phase II trial of panitumumab, erlotinib, and gemcitabine (PGE) versus erlotinib-gemcitabine (GE) in patients with untreated, metastatic pancreatic adenocarcinoma.

被引：4
|
作者：
Kim, G. P.
Foster, N. R.
Salim, M.
Flynn, P. J.
Moore, D. F.
Zon, R.
Mowat, R. B.
Wiesenfeld, M.
McCullough, A. E.
Alberts, S. R.
机构：
[1] Mayo Clin, Jacksonville, FL 32224 USA
[2] North Cent Canc Treatment Grp, Rochester, MN USA
[3] Allan Blair Canc Ctr, Saskatoon, SK, Canada
[4] Metro Minnesota Community Clin Oncol Project, St Louis Pk, MN USA
[5] Wichita Community Clin Oncol Program, Wichita, KS USA
[6] Michiana Hematol Oncol PC, South Bend, IN USA
[7] Toledo Community Hosp, Oncol Program, Toledo, OH USA
[8] Oncol Associates Cedar Rapids, Cedar Rapids, IA USA
[9] Mayo Clin, Scottsdale, AZ USA
[10] Mayo Clin, Rochester, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.4030
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4030
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer
    Andrew H. Ko
    Alan P. Venook
    Emily K. Bergsland
    R. Kate Kelley
    W. Michael Korn
    Elizabeth Dito
    Brian Schillinger
    Janet Scott
    Jimmy Hwang
    Margaret A. Tempero
    [J]. Cancer Chemotherapy and Pharmacology, 2010, 66 : 1051 - 1057
  • [22] A phase II study of isoflavone, gemcitabine, and erlotinib in locally advanced (LA) or metastatic pancreatic cancer
    Hammad, N.
    Philip, P. A.
    Shields, A. F.
    Sarkar, F. H.
    Abruzzese, J. L.
    Kaseb, A. O.
    Javle, M. M.
    Varadhachary, G. R.
    Wolff, R. A.
    El-Rayes, B. F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [23] A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer
    Ko, Andrew H.
    Venook, Alan P.
    Bergsland, Emily K.
    Kelley, R. Kate
    Korn, W. Michael
    Dito, Elizabeth
    Schillinger, Brian
    Scott, Janet
    Hwang, Jimmy
    Tempero, Margaret A.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (06) : 1051 - 1057
  • [24] Pulsed high-dose erlotinib with gemcitabine as second-line therapy for pancreatic adenocarcinoma.
    Larson, Christopher
    Reid, Tony R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [25] A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer
    Renouf, D. J.
    Tang, P. A.
    Hedley, D.
    Chen, E.
    Kamel-Reid, S.
    Tsao, M. S.
    Tran-Thanh, D.
    Gill, S.
    Dhani, N.
    Au, H. J.
    Wang, L.
    Moore, M. J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 (11) : 1909 - 1915
  • [26] A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer
    Bassel Fuad El-Rayes
    Philip A. Philip
    Fazlul H. Sarkar
    Anthony F. Shields
    Ann Marie Ferris
    Kenneth Hess
    Ahmad O. Kaseb
    Milind M. Javle
    Gauri R. Varadhachary
    Robert A. Wolff
    James L. Abbruzzese
    [J]. Investigational New Drugs, 2011, 29 : 694 - 699
  • [27] A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer
    El-Rayes, Bassel Fuad
    Philip, Philip A.
    Sarkar, Fazlul H.
    Shields, Anthony F.
    Ferris, Ann Marie
    Hess, Kenneth
    Kaseb, Ahmad O.
    Javle, Milind M.
    Varadhachary, Gauri R.
    Wolff, Robert A.
    Abbruzzese, James L.
    [J]. INVESTIGATIONAL NEW DRUGS, 2011, 29 (04) : 694 - 699
  • [28] A phase II trial of cabozantinib and erlotinib for patients with EGFR and c-MET co-expressing metastatic pancreatic adenocarcinoma.
    Gbolahan, Olumide B.
    Sehdev, Amikar
    Shahda, Safi
    Perkins, Susan
    Korc, Murray
    Loehrer, Patrick J.
    O'Neil, Bert H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [29] Preliminary results of a randomized phase II trial of first-line treatment of gemcitabine (G) versus erlotinib (E) versus gemcitabine and erlotinib (GE) in patients 70 years or older with advanced non-small cell lung cancer (NSCLC)
    Stinchcombe, T.
    Bradford, D. S.
    Lee, C. B.
    Moore, D. T.
    Bakri, K. M.
    Taylor, M. A.
    Crane, J. M.
    Schwartz, G.
    Hensing, T. A.
    Socinski, M. A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [30] Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer
    Okusaka, Takuji
    Furuse, Junji
    Funakoshi, Akihiro
    Ioka, Tatsuya
    Yamao, Kenji
    Ohkawa, Shinichi
    Boku, Narikazu
    Komatsu, Yoshito
    Nakamori, Shoji
    Iguchi, Haruo
    Ito, Tetsuhide
    Nakagawa, Kazuhiko
    Nakachi, Kohei
    [J]. CANCER SCIENCE, 2011, 102 (02) : 425 - 431
12345